On June 10, 2016, FDA is conducting a public meeting on Patient-Focused Drug Development for Neuropathic Pain associated with Peripheral Neuropathy. FDA is interested in obtaining patient input on the impact of Neuropathic Pain associated with Peripheral Neuropathy on daily life and patients’ views on currently available therapies to treat the condition.
This website will be updated as meeting materials are developed.
June 10, 2016
1:00 p.m. - 5:00 p.m.
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: http://peripheralneuropathypfdd.eventbrite.com
Registration to attend the meeting must be received by June 3, 2016.
Please use this link to join the Adobe Connect webcast room: Webcast
The link will begin working one hour before the start of the meeting. We recommend joining the webcast at least 15 minutes early to allow for any technical issues.
Submitting Comments to the Public Docket:
In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on August 10, 2016.
- Meeting Agenda
- Webinar: Background on FDA and Patient-Focused Drug Development
- Federal Register Notice
- Meeting Recording 1
- Meeting Recording 2
- Meeting Recording 3
- Meeting Recording 4
- Meeting Slides
- Transcript: Friday, June 10, 2016
- The Voice of the Patient: Neuropathic Pain Associated with Peripheral Neuropathy